an immunomodulating agent used topically, mainly in dermatology to treat inflammatory skin conditions such as atopic dermatitis (eczema). It belongs to the calcineurin inhibitor class, which includes tacrolimus, and works by suppressing the immune response that leads to inflammation

(can only be used for research purpose - cannot sell for drug manufacturing - limited long-term usage information)

Pimecrolimus is an immunomodulating agent used topically, mainly in dermatology to treat inflammatory skin conditions such as atopic dermatitis (eczema). It belongs to the calcineurin inhibitor class, which includes tacrolimus, and works by suppressing the immune response that leads to inflammation.

Key Aspects of Pimecrolimus:

• Mechanism of Action: Pimecrolimus inhibits calcineurin, blocking T-cell activation and reducing the production of inflammatory cytokines, which are responsible for symptoms like redness, itching, and swelling.
• Uses: Primarily prescribed for mild to moderate eczema, especially in cases where traditional corticosteroids are either ineffective or not suitable (e.g., long-term use or sensitive skin areas like the face).
• Application: It is applied as a topical cream (1% concentration), generally used in children over the age of 2 and adults.
• Advantages: Pimecrolimus is non-steroidal, reducing the risk of skin thinning (atrophy), a common side effect associated with corticosteroids. It is suitable for sensitive skin areas like the face, neck, and folds of the skin.
• Side Effects: Common side effects include a mild burning sensation or irritation at the application site. Because it affects the immune response, it may slightly increase the risk of viral infections like cold sores (herpes simplex).
• Long-term Use: It is often used intermittently rather than continuously, and prolonged use should be monitored by a healthcare provider to assess risks and benefits, particularly due to concerns about potential long-term cancer risks (although current evidence is not conclusive).